
In the STRONG-HF trial, the impact of non-cardiac comorbidities (NCCs) on high-intensity care (HIC) versus usual care (UC) was studied in stable patients with elevated NPs. Eight NCCs, including diabetes and stroke, were analyzed. HIC showed similar efficacy regardless of NCC number, with a 10.0% to 26.2% primary endpoint occurrence, compared to UC's 19.1% to 26.2%. Individual comorbidities also didn't significantly affect outcomes. Quality of life and adverse events showed no substantial differences based on NCCs. In the trial, NCCs didn't hinder HF-therapy up-titration or HIC's benefits. The study supports HIC for patients with multiple NCCs.
Like
Save
Share